CUMBERLAND PHARMACEUTICALS INC 8-K

What Happened Cumberland Pharmaceuticals Inc. announced the results of its annual meeting held April 21, 2026 (8-K filed April 24, 2026). Shareholders approved director elections for Class I nominees (vote results reported for Kenneth J. Krogulski and Caroline R. Young), ratified Carr, Riggs & Ingram, LLC as the company's independent registered public accounting firm for 2026, and approved both an advisory “say-on-pay” vote and the frequency of future say-on-pay votes.

Key Details

• Kenneth J. Krogulski: 9,561,336 votes for, 46,137 withheld — 99.52% of votes in favor.
• Caroline R. Young: 9,479,023 votes for, 128,450 withheld — 98.66% of votes in favor.
• Auditor ratification: Carr, Riggs & Ingram, LLC received 12,714,116 for, 19,033 against; 99.82% in favor (3,426 abstentions).
• Advisory votes on executive compensation: 9,350,671 for, 206,888 against, 49,914 abstentions (approved).
• Say-on-pay frequency: shareholders selected “Every Three Years” with 7,844,848 votes, versus 1,733,309 (Every Year) and 7,437 (Every Other Year); 21,879 abstentions.

Why It Matters These results show strong shareholder support for the named director nominees, continuity of the company’s independent auditor, and approval of the company’s executive compensation in an advisory vote. The selection of a triennial (“every three years”) cadence for future say-on-pay votes frames how often investors will have a formal advisory opportunity to vote on executive pay. Continuity in leadership and audit oversight can affect governance stability, regulatory compliance, and investor confidence.